Sarepta Therapeutics Inc
SRPT20.940USD
-15.239-42.12%
Close 06/16, 16:00（ET）Quotes delayed by 15 min
2.06BMarket Cap
8.75P/E TTM
More Details of Sarepta Therapeutics Inc Company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Company Info
Ticker SymbolSRPT
Company nameSarepta Therapeutics Inc
IPO dateJun 04, 1997
Founded at2013
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
Number of employees1372
Security typeOrdinary Share
Fiscal year-endJun 04
Address215 1st St Ste 415
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142-1213
Phone16172744000
Websitehttps://www.sarepta.com/
Ticker SymbolSRPT
IPO dateJun 04, 1997
Founded at2013
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R&D
Executive Vice President, Chief Scientific Officer, Head of R&D
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Cristin Rothfuss
Cristin Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
19.15K
+38.59%
Mr. Bilal Arif
Mr. Bilal Arif
Executive Vice President , Chief Technical Operations Officer
Executive Vice President , Chief Technical Operations Officer
16.42K
-16.76%
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R&D
Executive Vice President, Chief Scientific Officer, Head of R&D
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
By BusinessUSD
Name
Revenue
Proportion
PMO Products
967.17M
50.85%
ELEVIDYS
820.79M
43.15%
collaboration and other
114.02M
5.99%
By RegionUSD
Name
Revenue
Proportion
United States
1.64B
86.11%
Rest of World
150.25M
7.90%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
PMO Products
967.17M
50.85%
ELEVIDYS
820.79M
43.15%
collaboration and other
114.02M
5.99%
Shareholding Stats
Updated: Mon, May 19
Updated: Mon, May 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
Capital Research Global Investors
6.17%
State Street Global Advisors (US)
4.14%
Other
62.25%
Shareholders
Shareholders
Proportion
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
Capital Research Global Investors
6.17%
State Street Global Advisors (US)
4.14%
Other
62.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.91%
Investment Advisor/Hedge Fund
37.22%
Hedge Fund
9.45%
Individual Investor
4.42%
Research Firm
3.31%
Bank and Trust
1.10%
Pension Fund
1.10%
Sovereign Wealth Fund
1.09%
Venture Capital
0.33%
Institutional Shareholding
Updated: Mon, Jan 20
Updated: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1045
100.62M
102.55%
-5.73M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
2023Q1
946
86.41M
92.84%
-2.26M
2022Q4
996
84.01M
95.72%
-10.12M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital International Investors
8.70M
8.96%
+2.44M
+38.95%
Dec 31, 2024
The Vanguard Group, Inc.
9.07M
9.34%
+117.52K
+1.31%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
8.94M
9.21%
+162.26K
+1.85%
Dec 31, 2024
Capital Research Global Investors
5.93M
6.11%
+49.00
+0.00%
Feb 28, 2025
State Street Global Advisors (US)
4.07M
4.19%
-200.90K
-4.70%
Dec 31, 2024
Janus Henderson Investors
4.33M
4.46%
-30.19K
-0.69%
Dec 31, 2024
Barry (Richard J)
3.18M
3.28%
+2.38K
+0.07%
Mar 10, 2025
Avoro Capital Advisors LLC
2.56M
2.63%
--
--
Dec 31, 2024
Wellington Management Company, LLP
2.07M
2.13%
-657.84K
-24.13%
Dec 31, 2024
Farallon Capital Management, L.L.C.
2.87M
2.95%
+285.10K
+11.05%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
Global X Genomics & Biotechnology ETF
2.35%
First Trust NYSE Arca Biotechnology Index Fund
2.26%
iShares Neuroscience and Healthcare ETF
1.65%
Tema Neuroscience and Mental Health ETF
1.2%
WisdomTree BioRevolution Fund
0.92%
Harbor Human Capital Factor Unconstrained ETF
0.87%
SPDR S&P Biotech ETF
0.82%
VanEck Biotech ETF
0.74%
Invesco S&P MidCap 400 Pure Growth ETF
0.57%
Direxion Daily S&P Biotech Bull 3X Shares
0.54%
View more
Global X Genomics & Biotechnology ETF
Proportion2.35%
First Trust NYSE Arca Biotechnology Index Fund
Proportion2.26%
iShares Neuroscience and Healthcare ETF
Proportion1.65%
Tema Neuroscience and Mental Health ETF
Proportion1.2%
WisdomTree BioRevolution Fund
Proportion0.92%
Harbor Human Capital Factor Unconstrained ETF
Proportion0.87%
SPDR S&P Biotech ETF
Proportion0.82%
VanEck Biotech ETF
Proportion0.74%
Invesco S&P MidCap 400 Pure Growth ETF
Proportion0.57%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.54%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
